



Mucoactives in Acute Respiratory failure: Carbocisteine and Hypertonic saline

Co-enrolment Agreements in Place

ABBRUPT
ABC-ICU
ADAPT SEPSIS
AIRWAYS 3
ARDS NEUT
ASPECT
AspiFlu
ASTOP
AVONCAP
Barriers and Facilitators
BigpAK-2
BIS
BLINGIII
CAMELOT
CandiRes
CARDIAC Patients
Chance
CHEST
CKD after AKI
CoMiTED
CONDUCT-ICU
CoReCCT
CoReCCT_Awake Prone
CoReCCT_PROTECT airways
CoReCCT_Release
CoReCCT_UK NAVA
DINE
DISCUS
D-RISC-II
Emerald
EMT2 trial
Enceph-IG Trial
ENSARIA
EPICETUS
ERASER
Evaluating a POC device for sepsis
EVOCC
EXAKT

EXTEND
FLO-ELA
FREcycl-D
GENOMICC
GLA
GLASSHEART
GOLDILOCS
GuARDS
HAND-2
HEMOTION
IBD BioResource
IMET
InCyst
INFINIT
Innate Immunity
INSIGHT-ICU
IONA
iRehab
ISARIC
KHP Biobank
KLR Biobank
LicuiD
LIME ST
MAST
MecROX
MERIT
METABOLIC
MOSAICC
NEAT
OCCAMS
ORION-4
OXON-132_GSK Zanamivir
PANDOS
Paramedic -3
PHIND
PIVOTALboost
PNEUMO
POPPY Study
PQIP
PRECINCT
Prefibrillate
protect
REACT-SHOCK
REALIST
RECOVERY
REMAP CAP*
REVISE

RMCIP
SAPPHIRE
S-D21-C300
Sepsis Immunomics
SepTIC
SHORTER trial
SINFONIA
SMALL
SNAP
SOS
SQUEEZE
SRAVI
SWIFT
SWIPE 2
T4P
TANGLE
TARDIS.
TARGET-UP
Thrombolysis during machine perfusion
Tight K
TRACERx
TRAITS
UK-ROX
Venaseal
Vesper
VICToRY
VITAL
VITDALIZE

***excluding REMAP-CAP Cysteamine Domain** – it has been agreed that in sites operating both MARCH and the REMAP-CAP Cysteamine domain, non-COVID patients should be recruited to MARCH, and suspected/confirmed COVID patients should be recruited to the REMAP-CAP Cysteamine Domain.

Co-enrolment Not Permitted

A2B
ADFIRST
CO2**
EVIS
Good IDes2
HAP-Fast
MOPED
NOTACS
POP-I
RADAR
Rowtate
SC IL-1Ra
SEAL
SEIGLA

***within the 3 month timeframe*